Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 2013;20:648–59.
   PubMedGoogle Scholar
• DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643–53.
   PubMed Web of Science ®Google Scholar
• Fischhaber PL, Gall AS, Duncan JA, Hopkins PB. Direct demonstration in synthetic oligonucleotides that N,N′-bis(2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA. Cancer Res 1999;59:4363–8.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946;132:126–32.
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787–93.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 2002;3:1512–6.
   PubMedGoogle Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338–50.
   PubMed Web of Science ®Google Scholar
• Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol 1986;26:491–509.
   PubMed Web of Science ®Google Scholar
• Espinosa E, Zamora P, Feliu J, González Barón M. Classification of anticancer drugs–a new system based on therapeutic targets. Cancer Treat. Rev 2003;29:515–23.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 2017;7:339–48.
   PubMed Web of Science ®Google Scholar
• Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol 2015;12:3–20.
   PubMedGoogle Scholar
• Topcul M, Cetin I. Endpoint of cancer treatment: targeted therapies, Asian Pac. Asian Pac J Cancer Prev 2014;15:4395–403.
   PubMedGoogle Scholar
• Modugno M, Banfi P, Gasparri F, et al. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Exp Cell Res 2015;332:267–77.
   PubMed Web of Science ®Google Scholar
• Placzek WJ, Wei J, Kitada S, et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010;1:e40.
   PubMed Web of Science ®Google Scholar
• Bai P. Biology of Poly(ADP-Ribose) polymerases: the factotums of cell maintenance. Mol Cell 2015;58:947–58.
   PubMed Web of Science ®Google Scholar
• Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001;477:97–110.
   PubMed Web of Science ®Google Scholar
• Langelier MF, Pascal JM. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 2013;23:134–43.
   PubMed Web of Science ®Google Scholar
• Yu SW, Andrabi SA, Wang H, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006;103:18314–9.,
   PubMed Web of Science ®Google Scholar
• DeSimone RW, Currie KS, Mitchell SA, et al. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen 2004;7:473–94.
   PubMed Web of Science ®Google Scholar
• Khanam H. Shamsuzzaman, Bioactive Benzofuran derivatives: a review. Eur. J. Med. Chem 2015;97:483–504.
   PubMed Web of Science ®Google Scholar
• Nevagi RJ, Dighe SN, Dighe SN. Biological and medicinal significance of benzofuran. Eur J Med Chem 2015;97:561–81.
   PubMed Web of Science ®Google Scholar
• Dawood KM. An update on benzofuran inhibitors: a patent review. Expert Opin Ther Pat 2019;29:841–70.
   PubMed Web of Science ®Google Scholar
• Miao Y-h, Hu Y-h, Yang J, et al. Natural source, bioactivity and synthesis of benzofuran derivatives. RSC Adv 2019;9:27510–40.
   PubMed Web of Science ®Google Scholar
• Radadiya A, Shah A. Bioactive benzofuran derivatives: an insight on lead developments, radioligands and advances of the last decade. Eur J Med Chem 2015;97:356–76.
   PubMed Web of Science ®Google Scholar
• Goyal D, Kaur A, Goyal B. Benzofuran and Indole: promising scaffolds for drug development in Alzheimer’s Disease. ChemMedChem 2018;13:1275–99.
   PubMed Web of Science ®Google Scholar
• Hiremathad A, Patil MR, K. R C, et al. Benzofuran: an emerging scaffold for antimicrobial agents. RSC Adv 2015;5:96809–28.
   Web of Science ®Google Scholar
• Xu Z, Zhao S, Lv Z, et al. Benzofuran derivatives and their anti-tubercular, anti-bacterial activities. Eur J Med Chem 2019;162:266–76.
   PubMed Web of Science ®Google Scholar
• Chand, Rajeshwari K, Hiremathad A, Singh M, et al. A review on antioxidant potential of bioactive heterocycle benzofuran: natural and synthetic derivatives. Pharmacol. Rep 2017;69:281–95.
   PubMed Web of Science ®Google Scholar
• Alizadeh M, Jalal M, Hamed K, et al. Recent updates on anti-inflammatory and antimicrobial effects of furan natural derivatives. J Inflamm Res 2020;13:451–63.
   PubMed Web of Science ®Google Scholar
• Kwiecień H, Goszczyńska A, Rokosz P. Benzofuran small molecules as potential inhibitors of human protein kinases: a review. Curr Pharm Des 2016;22:879–94.
   PubMed Web of Science ®Google Scholar
• Flynn BL, Gill GS, Grobelny DW, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem 2011;54:6014–27.
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Baraldi PG, Carrion MD, et al. Design, synthesis and structure-activity relationship of 2-(3′,4′,5′-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization. Bioorg Med Chem 2009;17:6862–71.
   PubMed Web of Science ®Google Scholar
• Xia Y, Jin Y, Kaur N, et al. HIF-1α inhibitors: synthesis and biological evaluation of novel moracin O and P analogues. Eur J Med Chem 2011;46:2386–96.
   PubMed Web of Science ®Google Scholar
• Xie F, Zhu H, Zhang H, et al. In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor. Eur J Med Chem 2015;89:310–9.
   PubMed Web of Science ®Google Scholar
• Abdelhafez OM, Amin KM, Ali HI, et al. Design, synthesis and anticancer activity of benzofuran derivatives targeting VEGFR-2tyrosine kinase. RSC Adv 2014;4:11569–79.
   Web of Science ®Google Scholar
• Choi MJ, Jung KH, Kim D, et al. Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett 2011;306:190–6.
   PubMed Web of Science ®Google Scholar
• Gao C, Sun X, Wu Z, et al. A novel Benzofuran derivative Moracin N induces autophagy and apoptosis through ROS Generation In Lung Cancer. Front Pharmacol 2020;11:391.
   PubMed Web of Science ®Google Scholar
• Manna SK, Bose JS, Gangan V, et al. Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB. J Biol Chem 2010;285:22318–27.
   PubMed Web of Science ®Google Scholar
• Abd El-Karim SS, Anwar MM, Mohamed NA, et al. Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents. Bioorg Chem 2015;63:1–12.
   PubMed Web of Science ®Google Scholar
• Siddiqui SK, SahayaSheela VJ, Kolluru S, et al. Discovery of 3-(benzofuran-2-ylmethyl)-1H-indole derivatives as potential autophagy inducers in cervical cancer cells. Bioorg Med Chem Lett 2020;30:127431.
   PubMed Web of Science ®Google Scholar
• Mao ZW, Zheng X, Lin YP, et al. Design, synthesis and anticancer activity of novel hybrid compounds between benzofuran and N-aryl piperazine. Bioorg Med Chem Lett 2016;26:3421–4.
   PubMed Web of Science ®Google Scholar
• Xu K, Liu Y, Wang R, et al. Design, synthesis, and anticancer activities of Benzofuran–isatin hybrids tethered by pentylene and hexylene. J. Hetero. Chem 2019;56:2052–5.
   Web of Science ®Google Scholar
• De Moraes G, Teixeira PA, Pena LJ, Leite ACL. Isatin derivatives and their antiviral properties against arboviruses: a review. Mini Rev Med Chem 2019;19:56–62.
   PubMed Web of Science ®Google Scholar
• Guo H. Isatin derivatives and their anti-bacterial activities. Eur J Med Chem 2019;164:678–88.
   PubMed Web of Science ®Google Scholar
• Mathur G, Nain S. Recent advancement in synthesis of isatin as anticonvulsant agents, a review. Med Chem 2014;4:417–27.
   Google Scholar
• Phogat P, Singh P. A mini review on central nervous system potential of isatin derivatives. Cent Nerv Syst Agents Med Chem 2015;15:28–31.
   PubMedGoogle Scholar
• Ding Z, Zhou M, Zeng C. Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm 2020;353:e1900367
   PubMed Web of Science ®Google Scholar
• Hou Y, Shang C, Wang H, Yun J. Isatin-azole hybrids and their anticancer activities. Arch Pharm 2020;353:e1900272.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz HA, Eldehna WM, Keeton AB, et al. Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. Drug Des Devel Ther 2017;11:2333–46.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El Hassab MA, Abo-Ashour MF, et al. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: synthesis, biological and molecular dynamics investigations. Bioorg Chem 2021;110:104748.
   PubMed Web of Science ®Google Scholar
• El-Naggar M, Eldehna WM, Almahli H, et al. Novel Thiazolidinone/Thiazolo[3,2-a]Benzimidazolone-Isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in vitro biological evaluation. Molecules 2018;23:1420.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Al-Warhi T, et al. Development of 2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells. J Enzy Inhib Med Chem 2021;36:319–28.
   PubMed Web of Science ®Google Scholar
• Fares M, Eldehna WM, Abou-Seri SM, et al. Design, synthesis and in vitro antiproliferative activity of novel isatin-quinazoline hybrids. Arch Pharm 2015;348:144–54.
   PubMed Web of Science ®Google Scholar
• Montreal Q. Operating Environment (MOE), 10. Montreal: Chemical Computing Group Inc; 2009.
   Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813–23.
   PubMed Web of Science ®Google Scholar
• Acton EM, Narayanan VL, Risbood PA, et al. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 1994;37:2185–9.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J. Vis. Exp 2011;(50):2597–603.
   Google Scholar
• Marone M, Ferrandina G, Macchia G, et al. Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium. Oncology 2000;58:161–8.
   PubMed Web of Science ®Google Scholar
• Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003;10:76–100.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Nocentini A, Elsayed ZM, et al. Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer. ACS Med Chem Lett 2020;11:1022–7.
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, El Kerdawy AM, Aljaeed N, et al. Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors. Molecules 2020;25:2031–9.
   Google Scholar
• Elsayed ZM, Eldehna WM, Abdel-Aziz MM, et al. Development of novel isatin-nicotinohydrazide hybrids with potent activity against susceptible/resistant Mycobacterium tuberculosis and bronchitis causing-bacteria. J Enzyme Inhib Med Chem 2021;36:384–93.
   PubMed Web of Science ®Google Scholar
• Al-Rashood ST, Hamed AR, Hassan GS, et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzyme Inhib Med Chem 2020;35:831–9.
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, Abo-Ashour MF, Almahli H, et al. Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies. J Enzyme Inhib Med Chem 2020;35:1300–9.
   PubMed Web of Science ®Google Scholar